Celltrion Pharm Inc.
068760 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068760008
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청주시 청원구 오창읍 2산단로 82셀트리온제약, 청주시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Governance Information
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 8.9 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
|
Korean | 11.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.6 MB | ||
| 2025-06-23 00:00 |
Major Shareholding Notification
[기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 135.3 KB | ||
| 2025-05-30 00:00 |
Major Shareholding Notification
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 100.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-05-07 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 252.0 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion Pharm Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Celltrion Pharm Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion Pharm Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.
South Korea
290650
South Korea
290650
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
United States of America
LPTX
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
United States of America
LEGN
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
United States of America
LENZ
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
United States of America
LXEO
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
United States of America
LXRX
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS
Sweden
LIDDS
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
United States of America
LFCR
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
United States of America
LIMN
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Israel
LCTX